Skip to main content

Table 1 Baseline epidemiology, predisposing factors and clinical characteristics of fungal keratitis according to prior topical steroid use

From: Clinical analysis of microbiologically proven fungal keratitis according to prior topical steroid use: a retrospective study in South Korea

Characteristics

PS

(n = 30)

NPS

(n = 53)

p-value

Epidemiology

 Male sex

19 (63.3)

29 (54.7)

0.445

 Age, years

60.2 ± 14.9

64.6 ± 13.9

0.180

 Occupation

  Agriculture

14 (46.7)

25 (47.2)

0.965

  Non-agriculture

16 (53.3)

28 (52.8)

 

 Symptom duration, days

19.7 ± 15.4

15.0 ± 13.8

0.154

  Median (range)

14 (2–150)

10 (1–90)

0.127†

 Referral from primary eye clinic

11 (36.7)

4 (7.5)

0.001

Predisposing factors

 Corneal trauma

21 (70.0)

43 (81.1)

0.246

  Vegetable matter or wood

8 (26.7)

21 (39.6)

0.234

  Soil or water

9 (30.0)

16 (30.2)

0.986

  Other trauma

4 (13.3)

6 (11.3)

1.000*

 Previous OSD

13 (43.3)

12 (22.6)

0.048

  Herpetic keratitis

7 (23.3)

5 (9.4)

0.108*

  Punctate keratopathy

3 (10.0)

2 (3.8)

0.346*

  Old corneal opacity

2 (6.7)

3 (5.7)

1.000*

  Other keratopathya

1 (3.3)

2 (3.8)

1.000*

 Contact lens wear

1 (3.3)

4 (7.5)

0.649*

 Previous ocular surgery

10 (33.3)

10 (18.9)

0.139

 Systemic disease

12 (40.0)

21 (39.6)

0.973

  Diabetes mellitus

4 (13.3)

10 (18.9)

0.518

  Hypertension

7 (23.3)

12 (22.6)

0.943

Initial clinical characteristics

 Central corneal lesion

22 (73.3)

42 (79.2)

0.538

 Epithelial defect size (mm2)

12.7 ± 12.4

10.5 ± 11.2

0.404

   ≥ 10 mm2

13 (43.3)

16 (30.2)

0.228

 Depth of infiltration

  Superficial (0–50%)

14 (46.7)

36 (67.9)

0.057

  Deep (50–100%)

16 (53.3)

17 (32.1)

 

 Hypopyon

9 (30.0)

17 (32.1)

0.845

 Presenting BCVA (logMAR)

1.63 ± 0.96

1.47 ± 1.14

0.486

   < 0.1, Snellen

20 (66.7)

27 (51.9)

0.194

  1. Values are presented as mean ± standard deviation or number (%)
  2. BCVA best corrected visual acuity, NPS group of no prior topical steroid use, OSD ocular surface disease, PS group of prior topical steroid use
  3. *The p-value was calculated using Fisher’s exact test
  4. †The p-value was calculated using Kruskal-Wallis test
  5. aInclude neurotrophic keratopathy (PS), bullous keratopathy (NPS), and exposure keratopathy (NPS)